QuidelOrtho Gets 510(K) Clearance For Savanna Multiplex Molecular Platform And Savanna HSV 1+2/VZV PCR Assay
Portfolio Pulse from Benzinga Newsdesk
QuidelOrtho received FDA 510(k) clearance for its Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV PCR assay, enabling the company to market and sell these products for moderate or high complexity diagnostic testing in the U.S.
December 20, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
QuidelOrtho's FDA clearance for the Savanna platform and assay is likely to enhance its product offerings in the U.S. diagnostics market, potentially increasing revenue.
FDA clearances are significant milestones for medical device companies, often leading to increased sales and market penetration. The clearance of QuidelOrtho's Savanna platform and assay is directly related to the company's core business and is expected to have a positive impact on its stock price in the short term as it can now expand its product offerings in the U.S. market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100